AEF0117 is the most advanced drug candidate of the new pharmacological class, the CB1-SSi, developed by Aelis Farma. AEF0117 aims to treat disorders related to excessive cannabis use (addiction
An exceptional fiscal year 2021, marked by positive phase 2a results for AEF0117, the recognition of the first sub-licensing revenues thanks to the signature of an industrial partnership with Indivior PLC, and securing major grants for AEF0217 (EU’s Horizon 2020 program) and AEF0117 (NIH-NIDA USA).A solid financial.